ConductScience.org, home

Trial · NCT02498652

Outcomes14

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYCohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%))Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)Maximum Percentage (%) ChangeMEAN
PRIMARYCohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol.Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)mg/dLMEAN
PRIMARYCohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%))Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)Percentage (%) ChangeMEAN
PRIMARYCohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%))Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)Percentage (%) ChangeMEAN
PRIMARYCohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%))Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)Maximum Percentage (%) ChangeMEAN
SECONDARYMaximum Observed Concentration (Cmax)Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)µg/mLGEOMETRIC_MEAN
SECONDARYTime of Occurrence of Maximum Observed Concentration (Tmax)Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)hrGEOMETRIC_MEAN
SECONDARYArea Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)µg·hr/mLGEOMETRIC_MEAN
SECONDARYArea Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)µg·hr/mLGEOMETRIC_MEAN
SECONDARYApparent Terminal Half-life (t1/2)Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)hrGEOMETRIC_MEAN
SECONDARYNumber of Participants With Treatment-Emergent Adverse Events11 weeksNumber of participantsNUMBER
PRIMARYCohort 2 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol.Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)mg/dLMEAN
PRIMARYCohort 2 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%))Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)Percentage (%) ChangeMEAN
PRIMARYCohort 2 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%))Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)Percentage (%) ChangeMEAN

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02498652/outcomes